Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Emergent BioSolutions has entered into an agreement valued at approximately $174m for large-scale commercial production of drug substance for AstraZeneca Covid-19 vaccine candidate, AZD1222.
As part of the agreement, Emergent will offer contract development and manufacturing (CDMO) services to AstraZeneca through 2021.
This expands an $87m contract signed last month to provide development services, performance and process qualification, raw materials and for an initial capacity reservation.
AZD1222 is an adenovirus vector-based vaccine candidate co-developed by the University of Oxford and Vaccitech, while AstraZeneca obtained.